Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes
Zuzanna Ratka, Andrzej Gamian, Marta Woźniak · 2026
Read Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes by Zuzanna Ratka, Andrzej Gamian, Marta Woźniak (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13257165.txt.
Description
Zuzanna Ratka and co-authors review in 2026 the modest record of immune checkpoint drugs in ovarian cancer. These drugs transformed care for several cancers, yet ovarian tumors usually respond weakly. Trial evidence for single and combined checkpoint blockade is weighed in detail.
Single-drug treatment gave low response rates and little survival gain in unselected patients. Pairing two checkpoint drugs helped more in clear cell tumors but caused more immune side effects. Large first-line and maintenance trials mostly failed in groups chosen without biomarkers. Combinations with vessel-blocking drugs, PARP inhibitors, or chemotherapy helped select subgroups modestly. Early work on TIM-3 targets is noted as preliminary. Gynecologic oncologists get a clear message: progress depends on picking patients by biology, not treating all comers.
Catalog record
| CREATOR | Zuzanna Ratka, Andrzej Gamian, Marta Woźniak |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |